Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study
- PMID: 35672013
- PMCID: PMC9626030
- DOI: 10.1055/a-1869-7853
Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study
Abstract
Background: Treatment of ischemic stroke with recombinant tissue plasminogen activator for intravenous thrombolysis (IVT) must be delivered within a narrow time window after symptom onset. This effective hyperacute treatment can be administered after ruling out active anticoagulation with direct oral anticoagulants (DOACs). Whenever this is impractical, e.g., due to aphasia, plasmatic DOAC levels are measured with a consequent delay in the IVT decision-making process ranging from 30 to 60 minutes of time. This study will test the hypothesis that hyperacute point-of-care assessment of clotting time in the patient's whole blood has sufficient diagnostic accuracy to determine immediately whether stroke patients are pretreated with DOAC.
Methods and design: This will be a prospective single-center diagnostic accuracy study in 1,850 consecutive acute ischemic stroke patients at a tertiary stroke center in Saxony, Germany. Presence of active anticoagulation with DOAC will be determined by point-of-care quantification of clotting time via whole blood viscoelastic testing (ClotPro) using Russell venom viper and ecarin assay compared with high-performance liquid chromatography-tandem mass spectrometry as the reference standard.
Discussion: Viscoelastic point-of-care assessment of clotting time in whole blood might improve swift delivery of time-sensitive hyperacute treatment with IVT in stroke patients.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
T.S. received grants from the German Federal Ministry of Health and Kurt Goldstein Institut, royalties from Astra-zeneca for consulting and from Dresden International University for serving as a program director and a lecturer of the Master's Program in Clinical Research. None of these activities were related to the current study. The other authors report no conflict of interest.
Similar articles
-
Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke.Cerebrovasc Dis. 2019;48(1-2):17-25. doi: 10.1159/000502335. Epub 2019 Sep 4. Cerebrovasc Dis. 2019. PMID: 31484174
-
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17. Stroke. 2003. PMID: 12869717
-
Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.J Stroke Cerebrovasc Dis. 2018 Sep;27(9):2479-2483. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.004. Epub 2018 May 25. J Stroke Cerebrovasc Dis. 2018. PMID: 29807757
-
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.Stroke. 2020 Feb;51(2):533-541. doi: 10.1161/STROKEAHA.119.026426. Epub 2019 Dec 30. Stroke. 2020. PMID: 31884908
-
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].Rev Neurol (Paris). 2012 Jun;168(6-7):512-21. doi: 10.1016/j.neurol.2012.01.587. Epub 2012 May 28. Rev Neurol (Paris). 2012. PMID: 22647807 Review. French.
Cited by
-
Putting DOAC Doubts to Bed(Side): Preliminary Evidence of Comparable Functional Outcomes in Anticoagulated and Non-Anticoagulated Stroke Patients Using Point-of-Care ClotPro® Testing.J Clin Med. 2025 Aug 4;14(15):5476. doi: 10.3390/jcm14155476. J Clin Med. 2025. PMID: 40807095 Free PMC article.
-
Viscoelastic Point-of-Care Testing (ClotPro®) to Guide Intravenous Thrombolysis in Acute Ischemic Stroke Patients on DOACs: Replacing History with Hemostasis in a Proof-of-Concept Study.Neurol Int. 2025 Jul 1;17(7):103. doi: 10.3390/neurolint17070103. Neurol Int. 2025. PMID: 40710906 Free PMC article.
-
Enhancing Anticoagulation Monitoring and Therapy in Patients Undergoing Microvascular Reconstruction in Maxillofacial Surgery: A Prospective Observational Trial.J Pers Med. 2022 Jul 27;12(8):1229. doi: 10.3390/jpm12081229. J Pers Med. 2022. PMID: 36013177 Free PMC article.
-
Management and Prognosis of Acute Stroke in Atrial Fibrillation.J Clin Med. 2023 Sep 4;12(17):5752. doi: 10.3390/jcm12175752. J Clin Med. 2023. PMID: 37685819 Free PMC article. Review.
References
-
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group . Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587. - PubMed
-
- Second European-Australasian Acute Stroke Study Investigators Hacke W, Kaste M, Fieschi C.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 1998352(9136):1245–1251. - PubMed
-
- ECASS Investigators . Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329. - PubMed
-
- EXTEND Investigators . Ma H, Campbell B CV, Parsons M W. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–1803. - PubMed
-
- WAKE-UP Investigators . Thomalla G, Simonsen C Z, Boutitie F. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(07):611–622. - PubMed